Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial.
about
Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary ImmunodeficienciesA novel immunomodulatory treatment involving mycophenolate mofetil and corticosteroids for pediatric autoimmune cytopenias.Serendipity in splendid isolation: rapamycinMetabolic Factors that Contribute to Lupus PathogenesisOptimal Management of Autoimmune Lymphoproliferative Syndrome in Children.An Update on the Use of Immunomodulators in Primary Immunodeficiencies.Immunometabolism in systemic lupus erythematosus.Neutropenia in Patients with Common Variable Immunodeficiency: a Rare Event Associated with Severe Outcome.Autoimmunity/inflammation in a monogenic primary immunodeficiency cohortEvolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndrome.Autoimmune lymphoproliferative syndrome: more than a FAScinating disease.Nanomedicine approaches for sirolimus delivery: a review of pharmaceutical properties and preclinical studies.Antiphospholipid antibody-induced cellular responses depend on epitope specificity : implications for treatment of antiphospholipid syndrome.Drug repurposing for the treatment of glioblastoma multiforme.Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation.Autoimmunity and primary immunodeficiency: two sides of the same coin?Kaposi sarcoma-associated herpesvirus latency locus renders B cells hyperresponsive to secondary infectionsEvans syndrome: clinical perspectives, biological insights and treatment modalities
P2860
Q28066193-624434CF-306F-49D5-BB8D-799E5F4D0793Q33435295-73D303FE-B35E-4CC6-98F4-EB3B93EE73D0Q36443126-EE262F14-C395-4F19-9938-9B765960413CQ37612885-81F24769-3D7E-4244-BC72-80705FE97D09Q38823961-C10A2492-4DC8-4371-9757-7D7F4B0917B4Q39016299-C2F40450-F6C9-4DEB-B35C-7658705BD037Q39209701-EEF06D3E-29ED-4A4E-96CE-BF534871FD1BQ40079085-63D48BD3-D000-4F2E-9AA8-258C39F1146EQ41990601-13F243CC-3FBB-4518-A079-C2C824BEBCD3Q42325007-D596ED3F-9D83-4102-A6D8-FBC7E602CFABQ47151016-4A111706-69C7-4FDA-8354-35D4631ED2E6Q47351188-79BD2F25-6367-43B0-A3D4-2D6A9D446ECBQ47662342-109F5FB3-B170-4002-B11D-0630917FB0ABQ47948290-4E702B5E-F80C-4FF6-BBFB-0A9B415F8BFBQ48668293-332C9C8E-757F-43B9-AC26-568305B05512Q49644376-C4BC881A-837A-4879-AF44-20F918116A1DQ56345322-4704B39F-0DE1-4972-BDA6-CE171D309DFCQ57816250-A4E33934-0230-4C4E-9FC3-DDF839BFBCC7
P2860
Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Sirolimus is effective in rela ...... ive multi-institutional trial.
@ast
Sirolimus is effective in rela ...... ive multi-institutional trial.
@en
type
label
Sirolimus is effective in rela ...... ive multi-institutional trial.
@ast
Sirolimus is effective in rela ...... ive multi-institutional trial.
@en
prefLabel
Sirolimus is effective in rela ...... ive multi-institutional trial.
@ast
Sirolimus is effective in rela ...... ive multi-institutional trial.
@en
P2093
P2860
P50
P1433
P1476
Sirolimus is effective in rela ...... ive multi-institutional trial.
@en
P2093
Jack J Bleesing
James Casper
Karen L Bride
Kim Smith-Whitley
Michele P Lambert
Stephan A Grupp
Tiffaney Vincent
P2860
P356
10.1182/BLOOD-2015-07-657981
P407
P577
2015-10-26T00:00:00Z